Group 1 - The core viewpoint of the article highlights that Yuexiu Services (06626) has reported strong financial performance for the first half of 2025, with total revenue reaching 1.962 billion yuan, driven by a significant increase in property management income [1][2] - The commercial revenue accounted for 370 million yuan, representing 18.9% of total revenue, while non-commercial revenue was 1.592 billion yuan, making up 81.1% [1] - The company has maintained a robust growth rate in basic property management revenue, which increased by 19.2% year-on-year to 716 million yuan, marking the fourth consecutive year of approximately 20% growth in this segment [1] Group 2 - As of June 2025, Yuexiu Services managed a total area of 72.31 million square meters, with 91% located in first and second-tier core cities, contributing to high property fee prices and strong customer loyalty [1] - The company has established a solid high-net-worth project pool through precise urban and business strategy layouts, supported by the parent company Yuexiu Real Estate's commitment to high-quality delivery [1] - Yuexiu Services reported a cash and time deposit balance of 4.791 billion yuan, an increase of 89 million yuan from the end of 2024, positioning it as a "cash highland" in the industry [2] Group 3 - The company achieved a shareholder profit of 240 million yuan, maintaining a positive profit trend, and announced a high dividend payout ratio of 50%, reflecting confidence in future cash flows [2] - Analysts noted that basic services have transitioned from being a ceiling to a competitive moat for the company, as it successfully shifted from a scale-driven strategy to a quality-driven approach amid industry contraction [2]

智通财经APP讯，越秀服务(06626)公布2025年中期业绩，总收入为约人民币19.62亿元，同比增长 0.09%;公司拥有人应占溢利约2.4亿元，每股盈利0.16元，中期股息每股0.088港元。 截至2025年6月30日，合约项目515个(2024年12月31日：508个)，总合约面积9250万平方米(2024年12月 31日：8870万平方米)，合约面积增长4.2%;及在管项目444 个(2024年12月31日：437个)，总在管面积 7230万平方米(2024年12月31日：6930万平方米)，在管面积增长4.3%。 （原标题：越秀服务(06626)上半年公司拥有人应占溢利约2.4亿元 在管面积增长4.3%） ...

Group 1 - The core viewpoint of the article is that Yuexiu Services (06626) reported its mid-year results for 2025, showing stable revenue growth and an increase in contract and managed project areas [1] Group 2 - Total revenue for the first half of 2025 was approximately RMB 1.962 billion, representing a year-on-year growth of 0.09% [1] - The profit attributable to the company's owners was about RMB 240 million, with earnings per share of RMB 0.16 [1] - The interim dividend declared was HKD 0.088 per share [1] Group 3 - As of June 30, 2025, the company had 515 contracted projects, an increase from 508 projects as of December 31, 2024 [1] - The total contracted area reached 92.5 million square meters, up 4.2% from 88.7 million square meters as of December 31, 2024 [1] - The company managed 444 projects, an increase from 437 projects as of December 31, 2024 [1] - The total managed area was 72.3 million square meters, reflecting a growth of 4.3% from 69.3 million square meters as of December 31, 2024 [1]

Core Viewpoint - Yuexiu Services (06626.HK) reported its interim results for the first half of 2025, showing a total revenue of RMB 1.962 billion, with significant contributions from both non-commercial and commercial property management services [1] Financial Performance - Total revenue for the first half of 2025 was RMB 1.962 billion [1] - Revenue from non-commercial property management and value-added services amounted to RMB 1.5919 billion [1] - Revenue from commercial property management and operation services was RMB 369.9 million [1] - Gross profit margin stood at 21.3% [1] - Profit attributable to owners of the company reached RMB 239.7 million [1] Dividend Information - The board proposed an interim dividend of HKD 0.088 per share, equivalent to RMB 0.08 per share [1] - The dividend payout ratio is set at 50% [1] Operational Metrics - As of June 30, 2025, the total managed area was 72.3 million square meters [1] - The contracted area reached 92.5 million square meters [1]

（股份代號：06626） 截至二○二五年六月三十日止六個月的 中期業績公告 截至二○二五年六月三十日止六個月業績摘要 (ii) 自商業物業管理及運營服務所得收入為人民幣369.9百萬元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （在香港註冊成立的有限公司） – 1 – ‧ 總收入為人民幣1,961.9百萬元，其中： (i) 自非商業物業管理及增值服務所得收入為人民幣1,591.9百萬元；及 ‧ 截至二○二五年六月三十日，本集團在管面積為72.3百萬平方米，合約面積 為92.5百萬平方米。 ‧ 毛利率為21.3%。 ‧ 本公司擁有人應佔盈利為人民幣239.7百萬元。 ‧ 董事會建議宣派二○二五年中期股息每股0.088港元（相當於每股人民幣0.080 元），派息率為50%。 中期業績 越秀服務集團有限公司（「本公司」，及其附屬公司，「本集團」）董事（「董事」）會（「董 事會」）謹此宣佈本集團截至二○二五年六月三十日止六個月（「本期間」）的未經審核 ...

ck Code : 1093) 2025 Interim Results Presentation Aug. 2025 ININI China's Leading Innovative Pharmaceutical Enterprise R&D Capabilities 00 5 capacity of 250,000L R&D centers located in R&D platforms China & the U.S. 201010 + - 2401 Innovative drugs and R&D professionals new formulations Manufacturing Capabilities Commercialization Capabilities 2 10+ Production bases for pharmaceutical products Nano formulation production capacity of 20M doses/year; Biologics fermentation Chemical drugs production capacity o ...

格隆汇8月11日丨越秀服务(06626.HK)发布公告，公司将于2025年8月21日召开董事会会议，藉以审议并 批准包括截至2025年6月30日止的六个月期间的未经审核中期业绩，及考虑宣派中期股息（如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 承董事會命 越秀服務集團有限公司 余達峯 公司秘書 香港，二○二五年八月十一日 （於香港註冊成立的有限公司） （股份代號：06626） 董事會會議日期 越秀服務集團有限公司（「本公司」及其附屬公司「本集團」）董事（「董事」）會（「董事 會」）宣佈，二○二五年八月二十一日（星期四）將舉行董事會會議，以批准本集團截 至二○二五年六月三十日止六個月中期業績以及考慮派付中期股息（如有）及其他事 項。 於本公告刊發日期，董事會成員包括： 獨立非執行董事： 洪誠明、許麗君及梁耀文 執行董事： 王建輝、張成皓及張勁 非執行董事： 江国雄（主席）、張建国及楊昭煊 ...

第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 第 1 頁 共 10 頁 v 1.1.1 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06626 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,502,212,177 | | | | 1,502,212,177 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,502,212,177 | | 0 | | 1,502,212,177 | | 截至月份: | 2025年7月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及 ...

Investment Rating - The report maintains a "Positive" investment rating for the healthcare industry [9]. Core Insights - Chinese pharmaceutical companies are increasingly enhancing their original research capabilities, leading to a surge in high-quality innovative products gaining international recognition. This trend is facilitating the acceleration of domestic innovative drugs entering global markets through two primary pathways: "building ships" and "borrowing ships" [2][6]. - The total value of license-out transactions from China reached over $43 billion in 2024, accounting for nearly 20% of the global total, indicating a significant shift in the global pharmaceutical landscape as Chinese innovative drugs gain traction [6][17]. Summary by Sections Innovative Drug Globalization - Chinese innovative drug companies are transitioning from "following overseas" to "independent innovation," with a notable increase in original research capabilities. The number of Chinese companies participating in major international conferences like AACR and ASCO has reached historical highs, with 126 companies presenting nearly 300 new drug research results at the 2025 AACR conference [17][18]. - The number of original innovative drugs approved in China has increased from 11 in 2015 to 92 in 2024, with the proportion of globally developed first-in-class (FIC) drugs rising from 9% to 24% during the same period [21][22]. "Building Ships" and "Borrowing Ships" Models - "Building ships" refers to domestic companies independently conducting overseas clinical trials and obtaining market approvals. Notable examples include BeiGene's BTK inhibitor, which achieved over $2.6 billion in global sales, and Legend Biotech's CAR-T therapy, which reached $963 million in global sales in 2024 [25][26]. - "Borrowing ships" involves leveraging partnerships for international development and commercialization. The total value of license-out transactions in the Chinese innovative drug sector reached $51.9 billion in 2024, with over 50 transactions reported in the first half of 2025, totaling $48.4 billion [27][28]. Investment Perspective - The report emphasizes that the ongoing transformation in the healthcare sector, driven by innovative drug globalization, presents significant investment opportunities. Companies with strong cash flow, innovative capabilities, and established research platforms are particularly well-positioned for growth [43].